T cell therapy called AIC100, which targets the ICAM-1 protein, demonstrated encouraging responses and an acceptable safety ...

The Company's proprietary technology utilizing ICAM-1/LFA-1 interaction can potentially address all critical CAR T challenges such as toxicity, antigen loss, T-cell trafficking and exhaustion ...

The case comes from a phase 1 study of its ICAM-1 targeting CAR-T autologous candidate AIC100 in patients with relapsed/refractory poorly differentiated thyroid cancer (PDTC) and anaplastic ...

A new chimeric antigen receptor (CAR) T cell therapy called AIC100, which targets the ICAM-1 protein, demonstrated encouraging responses and an acceptable safety profile in patients with two types ...

AIC100 is a third generation CAR T cell therapy that works by binding to ICAM-1 on tumor cells to eliminate them. The CAR product co-expresses a protein, called somatostatin receptor 2 ...